Neurocrine Biosciences, Inc. (NASDAQ: NBIX)

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company’s products in clinical development stage include elagolix, which is in Phase III study for endometriosis; elagolix that is in Phase IIb study for uterine fibroids; Corticotropin-Releasing Factor Receptor1 Antagonist, which is in Phase I/II study for congenital adrenal hyperplasia and stress-related disorders; and Vesicular Monoamine Transporter 2 Inhibitor (VMAT2) that is in Phase III study for movement disorders, as well as Phase I study for tourette syndrome. Its research programs comprise VMAT2 for movement disorders, bipolar disorders, and schizophrenia; gonadotropin-releasing hormone (GnRH) antagonists for men’s and women’s health, and oncology; antiepileptic drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled receptors for other conditions. The company also develops pharmaceutical products for tardive dyskinesia, and other neurological and endocrine-related diseases and disorders.

Take a look at the 1-year chart of Neurocrine (NASDAQ: NBIX) below with added notations:

1-year chart of Neurocrine (NASDAQ: NBIX)

NBIX started from a $12 low back in July of last year and rallied from that low up to a $45 high in March. From there, the stock hit $45 as resistance a few more times forming a solid 52-week high resistance at $45 (blue). Last week the stock broke through that level, which should lead to higher prices overall.

ATTENTION SUBSCRIBERS!

Join our new Linkedin Group by clicking the link below:

Stock Trading & Investing for Everyone

The Tale of the Tape: NBIX broke its 52-week resistance at $45. The possible long position on the stock would be on a pullback down to that level with a stop placed under it. A break back below $45 could negate the forecast for a move higher.

Before making any trading decision, decide which side of the trade you believe gives you the highest probability of success. Do you prefer the short side of the market, long side, or do you want to be in the market at all? If you haven’t thought about it, review the overall indices themselves. For example, take a look at the S&P 500. Is it trending higher or lower? Has it recently broken through a key resistance or support level? Making these decisions ahead of time will help you decide which side of the trade you believe gives you the best opportunities.

No matter what your strategy or when you decide to enter, always remember to use protective stops and you’ll be around for the next trade. Capital preservation is always key!

Good luck!

Christian Tharp, CMT

Follow me on Twitter: @cmtstockcoach